Investors sold Merck shares heavily on Friday after the German pharmaceutical and chemicals company announced lacklustre quarterly results and suffered a regulatory setback for one of its key drugs.

A scientific committee of the European Medicines Agency rejected the use of Erbitux to treat a form of lung cancer, reducing the drug’s potential market in a decision that surprised the company and analysts. Merck shares fell 15 per cent.